Ono Pharmaceutical Co., Ltd.

BST:ON4 Stock Report

Market Cap: €5.7b

Ono Pharmaceutical Management

Management criteria checks 4/4

Ono Pharmaceutical's CEO is Gyo Sagara, appointed in Sep 2008, has a tenure of 17.75 years. total yearly compensation is ¥199.00M, comprised of 39.2% salary and 60.8% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth €1.71M. The average tenure of the management team and the board of directors is 2.2 years and 6 years respectively.

Key information

Gyo Sagara

Chief executive officer

JP¥199.0m

Total compensation

CEO salary percentage39.20%
CEO tenure17.8yrs
CEO ownership0.03%
Management average tenure2.2yrs
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gyo Sagara's remuneration changed compared to Ono Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

JP¥70b

Dec 31 2025n/an/a

JP¥62b

Sep 30 2025n/an/a

JP¥48b

Jun 30 2025n/an/a

JP¥43b

Mar 31 2025JP¥199mJP¥78m

JP¥50b

Dec 31 2024n/an/a

JP¥74b

Sep 30 2024n/an/a

JP¥95b

Jun 30 2024n/an/a

JP¥121b

Mar 31 2024JP¥190mJP¥78m

JP¥128b

Dec 31 2023n/an/a

JP¥128b

Sep 30 2023n/an/a

JP¥125b

Jun 30 2023n/an/a

JP¥115b

Mar 31 2023JP¥228mJP¥77m

JP¥113b

Compensation vs Market: Gyo's total compensation ($USD1.25M) is below average for companies of similar size in the German market ($USD2.59M).

Compensation vs Earnings: Gyo's compensation has been consistent with company performance over the past year.

CEO

Gyo Sagara (68 yo)

17.8yrs
Tenure
JP¥199,000,000
Compensation

Mr. Gyo Sagara has been the Chief Executive Officer at Ono Pharmaceutical Co., Ltd since April 01, 2024 and serves as it’s Director and served as its President since September 2008 until April 01, 2024 and...

Leadership Team

NamePositionTenureCompensationOwnership
Gyo Sagara
CEO & Chairman of the Board17.8yrsJP¥199.00m0.030%
€ 1.7m
Toichi Takino
President2.2yrsJP¥139.00m0.012%
€ 689.3k
Toshihiro Tsujinaka
Corp Sr Ex Offless than a yearJP¥112.00m0.0081%
€ 459.7k
Masaki Ito
Corporate Executive Officer and Div. Director of Corporate Strategy2.9yrsno datano data
Takehiro Yamada
Corporate Officer & Head of Risk and Compliance Management Department3.4yrsno datano data
Hiromu Habashita
Corporate Officerno datano datano data
Shinji Takai
Corporate Officer & Head of Medical Affairsno datano datano data
Satoshi Takahagi
Senior Director of EHS Promotion & Corporate Officerno datano datano data
Akira Takada
Corporate Executive Officer & Executive Director of CMC & Production1.4yrsno datano data
Tatsuya Okamoto
Corporate Officer & Executive Director of Clinical Developmentno datano datano data
Masayuki Tanigawa
Corporate Officerno datano datano data
Hirokazu Kitada
Corporate Officerless than a yearno datano data
2.2yrs
Average Tenure
62yo
Average Age

Experienced Management: ON4's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gyo Sagara
CEO & Chairman of the Board20yrsJP¥199.00m0.030%
€ 1.7m
Toichi Takino
President6yrsJP¥139.00m0.012%
€ 689.3k
Toshihiro Tsujinaka
Corp Sr Ex Off6yrsJP¥112.00m0.0081%
€ 459.7k
Shusaku Nagae
Independent Outside Director5yrsno datano data
Akiko Tanabe
Outside Audit & Supervisory Board Member6yrsno datano data
Yasuo Hishiyama
Outside Audit & Supervisory Board Member10yrsno datano data
Kiyoaki Idemitsu
Audit & Supervisory Board Member2yrsno data0.0038%
€ 217.6k
Masao Nomura
Independent Outside Director8yrsno datano data
Akiko Okuno
Independent Outside Director6yrsno datano data
Hironobu Tanisaka
Chairman of Audit Supervisory Board5yrsno data0.00043%
€ 24.4k
6.0yrs
Average Tenure
62yo
Average Age

Experienced Board: ON4's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 06:35
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ono Pharmaceutical Co., Ltd. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc